SSY Group (HK:2005) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SSY Group Limited has successfully obtained approval from China’s National Medical Products Administration for its drug Nikethamide, a central nervous system stimulant used to treat respiratory depression. This development marks a significant step for the company as it enhances its product portfolio in the pharmaceutical market.
For further insights into HK:2005 stock, check out TipRanks’ Stock Analysis page.